ArticleNucleic acids research2025
hnRNPL-CstF64 complex: coordinating CSR and LSR in IgH locus recombination dynamics through eRNA and NHEJ regulation.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differential regulation of immunoglobulin class switch recombination by the tumor suppressor p53.Scientific reports · 2026Article
- Phase separation as an emerging regulatory framework in antibody class switching and genome stability.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Class switch recombination (CSR) and locus suicide recombination (LSR) are critical processes involved in the immune system's ability to diversify antibody responses. Both are initiated by activation-induced cytidine deaminase, which induces DNA double-strand breaks (DSBs) at specific regions within the immunoglobulin heavy chain (IgH) locus. In CSR, DSBs occur at the switch (S) regions, allowing B cells to replace the IgM heavy chain constant region (CH) with other isotypes, thereby enhancing immune adaptability. This process is regulated by both cis and trans mechanisms, including the IgH super-enhancer 3' regulatory region (3'RR) and the production of enhancer RNAs (eRNAs). A recent study highlighted the role of MED12 in CSR through enhancer activation and the transcription of eRNA. Now, we show that heterogeneous ribonucleoprotein L (hnRNPL) acts as an additional regulator of CSR and LSR by forming an eRNA-associated complex with CstF64, a polyadenylation factor. This complex facilitates RNA polymerase II elongation and eRNA transcription at the 3'RR. Moreover, the hnRNPL/CstF64 complex promotes NHEJ-mediated DNA repair at both S and 3'RR regions, facilitating 53BP1 and Ku80 recruitment, thereby impacting the efficiency of CSR and LSR. This discovery highlights the intricate, multimodal regulation of these processes, linking eRNA transcription to DNA repair in the process of antibody diversification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.